Publications by authors named "Mathilde Cancel"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

144

Total Likes

6

Extended Reach

8,299

Social Features

2
P
Patterns of care and outcome of CIC-rearranged sarcoma patients: A nationwide study of the French sarcoma group.
Mehdi Brahmi, Nathalie Gaspar, Justine Gantzer, Maud Toulmonde, Pascaline Boudou-Rouquette, Emmanuelle Bompas, Nelly Firmin, Thibaud Valentin, Mathilde Cancel, Florence Duffaud

Cancer Med· April 2023

Videos about Article: user

1 1

View All Article and Social Media Activity
[
[Oncologists and hematologists' perspective on advance directives. A French national survey].
Amélie Cambriel, Kevin Serey, Adrien Pollina-Bachellerie, Mathilde Cancel, Jacques-Olivier Bay

Bull Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidelines to optimise ePROs monitoring for older patients under systemic cancer treatment from the French Society of Geriatric oncology (SoFOG) based on a delphi consensus.
Poppy Evenden, Mathilde Cancel, Florian Correard, Nicolas Bertrand, Claire Falandry

J Geriatr Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of the heterogeneity of cancer cells using single cell Ca profiling.
Amélie E Bura, Camille Caussette, Maxime Guéguinou, Dorine Bellanger, Alison Robert, Mathilde Cancel

Cell Commun Signal· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcome of advanced or recurrent endometrial carcinoma treated with chemotherapy: a French observational retrospective cohort: the ENDOVIE study.
Jerome Alexandre, Philippe Boudier, Elise Lavit, Bernard Asselain, Sheik Emambux, Mathilde Cancel

BMJ Open· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial.
Karim Fizazi, Gwénaël Le Teuff, Aude Fléchon, Lance Pagliaro, Josef Mardiak, Mathilde Cancel

J Clin Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FASTOCH: Feasibility of Electronic Patient-Reported Outcomes in Older Patients With Cancer-A Multicenter Prospective Study.
Mathilde Cancel, Carine Sauger, Julie Biogeau, Véronique Dardaine-Giraud, Thierry Lecomte

J Clin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort.
Jérémie Naffrichoux, Pierre Poupin, William Pouillot, Claude Linassier, Nathalie Rioux-Leclercq, Mathilde Cancel

Eur J Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endocrine therapy in advanced high-grade ovarian cancer: real-life data from a multicenter study and a review of the literature.
Marine Aubert, Laurent Mathiot, Hélène Vegas, Lobna Ouldamer, Claude Linassier, Mathilde Cancel

Oncologist· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment breaks in an oncology unit.
Fanny Vareille, François Chaumier, Claude Linassier, Donatien Mallet, Mathilde Cancel

BMJ Support Palliat Care· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncologists' perspective on advance directives, a French national prospective cross-sectional survey - the ADORE study.
Amélie Cambriel, Kevin Serey, Adrien Pollina-Bachellerie, Mathilde Cancel, Morgan Michalet

BMC Med Ethics· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variable effects of periprostatic adipose tissue on prostate cancer cells: Role of adipose tissue lipid composition and cancer cells related factors.
Mathilde Cancel, David Crottes, Dorine Bellanger, Frank Bruyère, Coralie Mousset

Prostate· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geriatric factors associated with overall survival in older patients with metastatic colorectal cancer.
Véronique Dardaine, Mathilde Cancel, Kaggwa Inyambo, Julie Biogeau, Carine Sauger

Clin Res Hepatol Gastroenterol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study.
Florence Duffaud, Jean-Yves Blay, Axel Le Cesne, Christine Chevreau, Pascaline Boudou-Rouquette, Mathilde Cancel

Br J Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
Jean-Yves Blay, Sylvie Chevret, Axel Le Cesne, Mehdi Brahmi, Nicolas Penel, Mathilde Cancel

Lancet Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.
Lucie Meynard, Derek Dinart, Blandine Delaunay, Aude Fléchon, Carolina Saldana, Mathilde Cancel

Eur J Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study.
Mirela Diana Ilie, Chiara Villa, Thomas Cuny, Christine Cortet, Guillaume Assie, Mathilde Cancel

Eur J Endocrinol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Novel Hormonal Agents (Abiraterone, Enzalutamide) on the Development of Visceral and/or Brain Metastases in Patients With Bone-metastatic Castration-resistant Prostate Cancer.
Cédric Pobel, Emeline Laurent, Aline-Marie Florence, Gaëlle Fromont, Gilles Calais, Mathilde Cancel

Clin Genitourin Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interplay between Prostate Cancer and Adipose Microenvironment: A Complex and Flexible Scenario.
Mathilde Cancel, William Pouillot, Karine Mahéo, Alix Fontaine, David Crottès

Int J Mol Sci· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data.
Laurence Albiges, Daniel Y C Heng, Jae Lyun Lee, Stephen Walker, Anders Mellemgaard, Mathilde Cancel

Eur J Cancer· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Yann-Alexandre Vano, Réza Elaidi, Mostefa Bennamoun, Christine Chevreau, Delphine Borchiellini, Mathilde Cancel

Lancet Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
Olivier Trédan, Magali Provansal, Cyril Abdeddaim, Audrey Lardy-Cleaud, Anne-Claire Hardy-Bessard, Mathilde Cancel

Gynecol Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphovascular invasion as a criterion for adjuvant chemotherapy for FIGO stage I-IIa clear cell carcinoma, mucinous, low grade serous and low grade endometrioid ovarian cancer.
Julie Delvallée, Mathilde Cancel, Gilles Body, Sofiane Bendifallah, Cyril Touboul

J Gynecol Obstet Hum Reprod· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales).
Mathilde Cancel, Gaelle Fromont, Cyriac Blonz, Christine Chevreau, Nathalie Rioux-Leclercq

Eur J Cancer· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer.
Cedric Pobel, Edouard Auclin, Diego Teyssonneau, Brigitte Laguerre, Mathilde Cancel

Cancer Med· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis